Lymphoscintigraphy in patients with malignant melanoma: a quantitative and qualitative evaluation of its usefulness.
Lymphoscintigraphy using 99mTcSb2S3 colloid was performed in 32 patients with malignant melanoma. Subcutaneous injections were made peritumorally in 20 patients and dorsopedally in 12 patients. Regional lymph node dissections were carried out on the following day in 16 patients and the resected lymph nodes were weighted, measured for radioactivity, and examined by light microscopy. Lymph flow to regional lymph nodes was shown in all but 2 patients. Twenty-nine of 239 lymph nodes contained metastases. Radioactivity was demonstrated in 17 of these nodes. In 5 of 11 patients with metastatic disease, the highest uptake was found in cancerous lymph nodes. The specific activity-uptake distribution in isolated ilio-inguinal lymph nodes after a dorsopedal injection was log-normal with a mean of 0.05%/g indicating a good saturation of colloid particles. This investigation concludes that the observed lymph flow directions in patients injected peritumorally are of value for the follow-up. Quantitative lymphoscintigraphy in patients with melanoma of the lower extremities is, however, of no value for excluding ilio-inguinal lymph node metastases.
D000818:Animals; D000965:Antimony / Q000008:administration & dosage; D001365:Axilla; D006119:Groin; D006801:Humans; D007279:Injections, Subcutaneous; D008198:Lymph Nodes / Q000000981:diagnostic imaging*; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000000981:diagnostic imaging* / Q000473:pathology / Q000556:secondary; D051379:Mice; D011817:Rabbits; D011877:Radionuclide Imaging; D012878:Skin Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D013667:Technetium / Q000008:administration & dosage; D017556:Technetium Compounds
D017556:Technetium Compounds; C019096:technetium Tc 99m antimony sulfide; D013667:Technetium; D000965:Antimony